论文部分内容阅读
目的探讨乳腺癌新辅助联合淋巴化疗后前哨淋巴结活检的价值。方法 40例局部晚期乳腺癌患者随机分为试验组及对照组两组,分别进行新辅助联合淋巴化疗及仅进行新辅助化疗,对治疗后可切除病例(试验组治疗后可切除病例归入A组,对照组治疗后可切除病例归入B组)行前哨淋巴结活检、腋淋巴结清扫术,对活检资料及腋淋巴结情况进行分析。结果 A组患者检出率88.24%,准确性80%,假阴性率35.71%;B组检出率90.91%,准确性90%,假阴性率11.11%。两组准确性、假阴性率比较,差异均有统计学意义(P<0.05)。结论乳腺癌新辅助化疗联合淋巴化疗会干扰前哨淋巴结活检结果。
Objective To investigate the value of sentinel lymph node biopsy after neoadjuvant lymphopexy in breast cancer. Methods Forty patients with locally advanced breast cancer were randomly divided into two groups: experimental group and control group. Neoadjuvant lymphoid chemotherapy and neoadjuvant chemotherapy alone were performed. After resection, resectable cases (resectable group A Group, the control group of resectable cases were classified into group B) sentinel lymph node biopsy, axillary lymph node dissection, biopsy data and axillary lymph node analysis. Results The detection rate of group A was 88.24%, the accuracy was 80% and the false negative rate was 35.71%. The detection rate of group B was 90.91%, the accuracy was 90% and the false negative rate was 11.11%. The accuracy of the two groups, false negative rate, the difference was statistically significant (P <0.05). Conclusion Neoadjuvant chemotherapy combined with lymphatic chemotherapy in breast cancer can interfere with sentinel lymph node biopsy results.